Trial Profile
Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or MET Exon 14 Mutation or ROS1 Translocation (METROS)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms METROS
- 09 Aug 2022 Results (n=64) of long-term outcomes analysis of ROS1+ patients with brain metastases (BM). presented at the 2022 World Conference on Lung Cancer
- 01 Apr 2020 Results (N=10), providing detailed molecular data for the 10 patients with MET exon 14 mutations, published in the Clinical Cancer Research
- 15 Aug 2019 Results (n=52, data cut off: Sep 2017) investigating activity of crizotinib in patients harboring MET or ROS1 alterations published in the Clinical Cancer Research